Bill
Bill > HF14
IA HF14
IA HF14A bill for an act relating to the controlled substance crystalline polymorph psilocybin.(See HF 383.)
summary
Introduced
01/14/2025
01/14/2025
In Committee
01/14/2025
01/14/2025
Crossed Over
Passed
Dead
Introduced Session
91st General Assembly
Bill Summary
This bill relates to the controlled substance crystalline polymorph psilocybin. Current law categorizes the controlled substance psilocybin as a schedule I, hallucinogenic substance (Code section 124.201(4)(s)). The bill provides that notwithstanding Code section 124.204(4), a drug that contains the pharmaceutical composition of crystalline polymorph psilocybin shall be immediately removed from schedule I upon its approval by the United States food and drug administration and rescheduled based upon the recommendations of the United States food and drug administration and its listing in the federal Controlled Substances Act. The bill provides that upon the rescheduling of psilocybin, it shall be lawful to prescribe, distribute, and market the pharmaceutical composition of crystalline polymorph psilocybin. Current penalties for the possession of psilocybin range from a serious misdemeanor to a class “B” felony.
AI Summary
This bill addresses the legal status of crystalline polymorph psilocybin (also known as COMP 360), a specific form of the psychedelic substance psilocybin. Currently classified as a Schedule I controlled substance, the bill proposes an automatic rescheduling mechanism once the drug receives approval from the United States Food and Drug Administration (FDA). Specifically, upon FDA approval, the drug would be immediately removed from Schedule I and reclassified according to the FDA's recommendations and its listing in the federal Controlled Substances Act. Once rescheduled, the bill would make it legally permissible to prescribe, distribute, and market the pharmaceutical composition of crystalline polymorph psilocybin. This legislation represents a significant shift in the legal treatment of psilocybin, potentially recognizing its medical potential by creating a pathway for its legal medical use after formal FDA approval, while maintaining regulatory oversight through the controlled substances scheduling process.
Committee Categories
Health and Social Services
Sponsors (1)
Last Action
Withdrawn. H.J. 418. (on 02/24/2025)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.legis.iowa.gov/legislation/BillBook?ga=91&ba=HF14 |
| BillText | https://www.legis.iowa.gov/docs/publications/LGI/91/attachments/HF14.html |
Loading...